AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04776954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming System
Description: The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin.
Study NCT04776954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Blanket Warming System
Description: This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
Study NCT05724446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
Study NCT05724446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension, 1%
Description: Microfine sterile ophthalmic suspension of dense and whitish appearance.
Study NCT04924374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Transplant plus anti PD1 therapy
Description: Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (>30g/day).~anti PD1 therapy every 2-3 weeks
Study NCT04924374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti PD1 therapy
Description: anti PD1 therapy every 2-3 weeks
Study NCT05762484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser hair removal
Description: Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
Study NCT05762484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1 % Topical Lotion
Description: Clindamycin 1% lotion if needed
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.
Study NCT06008093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
Study NCT05540873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB-103
Description: Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
Study NCT06386627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stimulus response task
Description: Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
Study NCT06386627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation to assess the integrity of corticospinal connections
Study NCT05966779 — intervention group
Intervention type: OTHER
Intervention: modified CDT physical therapy protocol, based on Godoy's Method
Description: modified CDT physical therapy protocol
Study NCT05800405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05800405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Receive CAR-T per standard of care
Study NCT05800405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05800405 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT05800405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Receive leukapheresis
Study NCT05800405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05800405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06176716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study NCT05956626 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OCU410ST
Description: Subretinal Administration of OCU410ST
Study NCT04738825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)
Description: Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5).
Study NCT05411640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with Blood flow restriction
Description: Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
Study NCT05411640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise without Blood flow restriction
Description: Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
Study NCT05411640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Education and dietary modification
Description: Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
Study NCT04772664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multispecies-Probiotic
Description: Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
Study NCT04772664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
Study NCT06249919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
Study NCT06249919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
Study NCT05442697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF treatment
Description: Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
Study NCT05442697 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
Study NCT04986631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Tablets
Description: Topiramate intervention
Study NCT06214117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
Study NCT06214117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
Study NCT06013878 — intervention group
Intervention type: OTHER
Intervention: Transfer Training with clinician
Description: Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
Study NCT05023512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health
Description: Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
Study NCT05247749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVIVO Confocal Endomicroscopy System
Description: Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
Study NCT04891458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients received lighter sedation with propofol after spinal anesthesia.
Description: MOAA/S 0-2.
Study NCT04891458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients received heavier sedation with propofol after spinal anesthesia
Description: MOAA/S 3-5.
Study NCT04891458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients received lighter sedation with dexmedetomidine after spinal anesthesia
Description: MOAA/S 0-2.
Study NCT04891458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients received heavier sedation with dexmedetomidine after spinal anesthesia.
Description: MOAA/S 3-5.
Study NCT05569837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular meal pattern
Description: 6 meals every day
Study NCT05569837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irregular meal pattern
Description: It consists of consuming a different number of meals every day (between 3 and 9).
Study NCT06554470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Methotrexate
Description: Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
Study NCT06554470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Methotrexate
Description: Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
Study NCT06553196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATAspire Web-app
Description: Substance misuse prevention education and adaptive coping skills
Study NCT05843136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
Study NCT06060535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Attempt Risk Model Care Pathway
Description: The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
Study NCT06060535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide Attempt Risk Model Care Pathway
Description: The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
Study NCT05843136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy treatment
Description: this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
Study NCT06247514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BEET Diabetes Program
Description: The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
Study NCT06247514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy Guided Self-Help
Description: 6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert.
Study NCT06715748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Monoester (KE)
Description: Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
Study NCT06715748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
Study NCT05499000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional freedom technique
Description: Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS.
Study NCT06719336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy
Description: Twice-daily thoracic radiotherapy at a dose of 54 Gy in 30 fractions with IMRT and VMAT
Study NCT06719336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab or durvalumab
Description: atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
Study NCT06719336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atezolizumab or durvalumab
Description: atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
Study NCT06062134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
Study NCT06062134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast
Description: 20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
Study NCT06750094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered.
Study NCT06750094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered.
Study NCT06750094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered as chemotherapy regimen.
Study NCT06750094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan will be administered as chemotherapy regimen.
Study NCT04164277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Component.
Description: Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.